Weitzner Yonker Kaine MD PA — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$65,071	3
2022	Research	$48,658	2
2021	Research	$266,727	13
2020	Research	$232,949	8
2019	Research	$116,866	16

Breakdown

Who paid Research payments · program years 2019–2025

Ucb SA $627,358 26 payments
Eli Lilly and Company $69,718 3 payments
Sanofi US Services Inc. $16,752 10 payments
Takeda Pharmaceuticals U.S.A., Inc. $12,060 2 payments
UCB GmBH $4,382 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis $317,705 8 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis $120,397 7 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axia $82,825 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis $56,038 2 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $53,011 1 payment
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis $22,954 4 payments
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis. $21,936 1 payment
A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA) $16,752 10 payments
A Multicenter Long-Term Extension Study of 104 Weeks Including A Double Blind Placebo Controlled 40 Week Randomized Withdrawal Retreatment Period to Evaluate the Maintenance of Treatment Effect of Ixekizumab Ly2439821 in Patients With Axial Spondyloarthritis $16,707 2 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) $12,060 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.